Rituximab therapy in idiopathic membranous nephropathy: A 2-year study

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 12, 2010, Pages 2188-2198

  Fervenza, Fernando C ^a   Abraham, Roshini S ^b   Erickson, Stephen B ^a   Irazabal, Maria Valentina ^a   Eirin, Alfonso ^a   Specks, Ulrich ^b   Nachman, Patrick H ^c   Bergstralh, Eric J ^b   Leung, Nelson ^a   Cosio, Fernando G ^a   Hogan, Marie C ^a   Dillon, John J ^a   Hickson, LaTonya J ^a   Li, Xujian ^b   Cattran, Daniel C ^d  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CREATININE; CYCLOSPORIN; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; FLUSHING; FOLLOW UP; HEART INFARCTION; HUMAN; IDIOPATHIC DISEASE; IMMUNOLOGICAL MONITORING; INFLUENZA; LYMPHOCYTE SUBPOPULATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NOSE CONGESTION; PNEUMONIA; PROTEINURIA; RASH; RELAPSE; REMISSION; SIDE EFFECT; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; B-LYMPHOCYTES; CD4-CD8 RATIO; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 78650360097     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05080610     Document Type: Article

References (34)

1. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008 (Pubitemid 350273646)
2. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589, 2004 (Pubitemid 39062719)
3. Dorner T, Jacobi AM, Lipsky PE: B cells in autoimmunity. Arthritis Res Ther 11: 247, 2009
4. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54: 613-620, 2006 (Pubitemid 43228639)
5. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW: Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 103: 885-894, 1999 (Pubitemid 29297593)
6. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580-3590, 2004 (Pubitemid 39488683)
7. Roll P, Dorner T, Tony HP: Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58: 1566-1575, 2008 (Pubitemid 351847509)
8. Kerjaschki D, Neale TJ: Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7: 2518-2526, 1996 (Pubitemid 27469557)
9. Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 128: 2453-2457, 1982 (Pubitemid 12124460)
10. Zhu LP, Cupps TR, Whalen G, Fauci AS: Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 79: 1082-1090, 1987 (Pubitemid 17065486)
11. Zucchelli P, Ponticelli C, Cagnoli L, Aroldi A, Beltrandi E: Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy. Am J Nephrol 8: 15-20, 1988
12. Kuroki A, Iyoda M, Shibata T, Sugisaki T: Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 68: 302-310, 2005 (Pubitemid 43181389)
13. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
14. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL, North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
15. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
16. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937, 2007
17. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
18. Branten AJ, Vervoort G, Wetzels JF: Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 20: 707-711, 2005 (Pubitemid 40520646)
19. Hladunewich MA, Lemley KV, Blouch KL, Myers BD: Determinants of GFR depression in early membranous nephropathy. Am J Physiol 284: F1014-F1022, 2003
20. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
21. Praga M, Barrio V, Juarez GF, Luno J: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71: 924-930, 2007 (Pubitemid 46663803)
22. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248-256, 2007
23. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110: 2561-2564, 2007
24. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V: Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory lowgrade or follicular non-Hodgkin's lymphoma. [see comment]. Ann Oncol 10: 655-661, 1999 (Pubitemid 29342370)
25. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998
26. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48: 1332-1342, 2003 (Pubitemid 36554532)
27. Bernard F, Romano A, Granel, B: Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjogren's syndrome [in French]. Rev Med Interne 31: 116-127
28. Sfikakis PP, Boletis JN, Tsokos GC: Rituximab anti-B-cell therapy in systemic lupus erythematosus: Pointing to the future. Curr Opin Rheumatol 17: 550-557, 2005 (Pubitemid 41527814)
29. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 52: 501-513, 2005 (Pubitemid 40216314)
30. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143, 2000
31. Cattran D: Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 16: 1188-1194, 2005 (Pubitemid 41716503)
32. Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernandez-Juarez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernandez-Vega F, Praga, M: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 21: 697-704, 2010
33. Salama AD, Pusey CD: Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2: 221-230, 2006 (Pubitemid 43787288)
34. Calabrese LH, Molloy ES: Therapy: Rituximab and PML risk-informed decisions needed!. Nat Rev Rheumatol 5: 528-529, 2009